Powerful drug development platform

Revere’s innovative platform combines in silico modeling and proprietary assays with high-throughput screening capabilities to discover novel Rac1 and Cdc42 inhibitors. These enable delivery of novel targeted therapeutics.

Focusing on areas of high unmet need

We are at the leading edge of developing small molecules to inhibit Rho GTPase activation, creating medicines to address cancers and other diseases inadequately treated with standard of care therapies.

New Developments